Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Evaxion Biotech A/S

We are a clinical-stage AI-immunology™ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. 
We are currently in the clinic with our two lead product candidates, EVX-01 and EVX-02, for the treatment of various cancers.

We have four proprietary AI prediction models: PIONEER, ObsERV, EDEN and RAVEN.

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue						73.11K -
cost of revenue		80.98K -	105.72K 30.54%	343.45K 224.87%	571.32K 66.35%
gross profit		-80.98K -	-105.72K 30.54%	-343.45K 224.87%	-571.32K 66.35%	73.11K 112.80%
selling and marketing expenses						15.51K -
general and administrative expenses	1.88M -	2.63M 39.72%	5.67M 115.36%	6.25M 10.32%	8.21M 31.31%	10.08M 22.79%
selling general and administrative expenses	1.88M -	2.63M 39.72%	5.67M 115.36%	6.25M 10.32%	8.21M 31.31%	10.09M 22.98%
research and development expenses	3.73M -	8.22M 120.33%	10.90M 32.69%	19.58M 79.63%	17.06M 12.90%	11.59M 32.02%
other expenses	15K -	16K 6.67%
cost and expenses	5.63M -	10.86M 93.05%	16.57M 52.52%	25.83M 55.93%	25.26M 2.21%	22.30M 11.72%
operating expenses	5.63M -	10.86M 93.05%	16.57M 52.52%	25.83M 55.93%	25.26M 2.21%	21.69M 14.15%
interest expense	698K -	1.22M 75.07%	223K 81.75%	915K 310.31%	1.51M 64.81%	897K 40.52%
ebitda	-5.55M -	-10.77M 94.07%	-16.35M 51.79%	-23.80M 45.52%	-22.43M 5.72%	-21.62M 3.65%
operating income	-5.63M -	-10.86M 93.05%	-16.57M 52.52%	-25.83M 55.93%	-25.26M 2.21%	-22.23M 12.00%
depreciation and amortization	74K -	90K 21.62%	216K 140%	2.04M 843.98%	2.83M 38.84%	615.95K 78.24%
total other income expenses net	53K -	-1.16M 2,283.02%	-7K 99.39%	1.12M 16,157.14%	1.32M 17.70%	-719.10K 154.35%
income before tax	-6.27M -	-12.02M 91.71%	-16.57M 37.90%	-24.71M 49.08%	-23.94M 3.11%	-22.95M 4.14%
income tax expense	-735K -	-825K 12.24%	-1.56M 88.73%	-178K 88.57%	-772K 333.71%	-791.22K 2.49%
net income	-5.54M -	-11.20M 102.26%	-15.02M 34.15%	-24.53M 63.35%	-23.17M 5.56%	-22.16M 4.36%
weighted average shs out	1.92M -	1.62M 15.63%	1.62M 0%	1.95M 20.34%	2.36M 21.27%	2.73M 15.64%
weighted average shs out dil	1.92M -	1.62M 15.63%	1.62M 0%	1.95M 20.34%	2.36M 21.27%	2.73M 15.64%
eps	-2.88 -	-6.91 139.93%	-9.27 34.15%	-12.58 35.71%	-9.80 22.10%	-8.11 17.24%
epsdiluted	-2.88 -	-6.91 139.93%	-9.27 34.15%	-12.58 35.71%	-9.80 22.10%	-8.11 17.24%

NASDAQ:EVAX

Evaxion Biotech A/S

Last Close

2.91

26/07 20:00

Market Cap

16.59M

Beta: 0.56

Volume Today

11.28K

Avg: 118.15K

PE Ratio

−0.47

PFCF: 6.47

Preview